Spatial Adversities of the Commercialization of Main Roads: A Case Study of Main Road, Samanabad, Lahore
Journal of Art, Architecture and Built Environment · 2018
DOI: 10.32350/jaabe.12.03 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Art, Architecture and Built Environment, 2018. Verfasst von Umair Zia Malik und 2 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
The negative impacts of land-use commercialization on built environment were studied in this research. Data was collected from the target population residing on Main Road Samanabad, Lahore. Data was collected through stratified sampling technique and analyzed in SPSS. The variables were correlated to draw conclusions. It was discovered that it is not only the tangible infrastructure that is responsible for the degradation of the built environment but intangible factors such as the existing policy on acquiring No Objection Certificate (NOC) also cause its deterioration. Furthermore, site-specific regulatory procedures need to be implemented. These loopholes were identified and organized in terms of their urgency of action and recommendations were prepared according to the research findings.
Zitieren
APA
Malik, U. Z., Gulzar, S., & Awan, M. (2018). Spatial Adversities of the Commercialization of Main Roads: A Case Study of Main Road, Samanabad, Lahore. Journal of Art, Architecture and Built Environment. https://doi.org/10.32350/jaabe.12.03
Vancouver
Malik UZ, Gulzar S, Awan M. Spatial Adversities of the Commercialization of Main Roads: A Case Study of Main Road, Samanabad, Lahore. Journal of Art, Architecture and Built Environment. 2018. doi:10.32350/jaabe.12.03
BibTeX
@article{Malik2018,
author = {Malik, Umair Zia and Gulzar, Saima and Awan, Muhammad},
title = {Spatial Adversities of the Commercialization of Main Roads: A Case Study of Main Road, Samanabad, Lahore},
journal = {Journal of Art, Architecture and Built Environment},
year = {2018},
doi = {10.32350/jaabe.12.03}
}
EUVIMED